Ocuphire Pharma, Inc. OCUP
At closeOct 23, 2024, 4:00 PM EDT
52-week range unavailable
- Market cap
- 31.74M
- Revenue (ttm)
- 16.45M
- Profit margin
- -85.75%
- Shares out
- 26.20M
- Forward P/E
- -1.30
- Volume
- 675.97K
- Open
- 1.33
- Previous close
- 1.17
- Day's range
- 1.07 – 1.36
- Beta
- 0.31
- Analysts
- Buy
- Price target
- 13.67 (+1068.4%)
- Earnings date
- Nov 11, 2024
Key statistics
- Enterprise value
- -11.81M
- PEG ratio
- 0.00
- Price / sales
- 1.93
- Price / book
- 0.75
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -69.70%
- Free cash flow
- -8.70M
- Total cash
- 41.41M
- Total debt
- 0
- Return on equity
- -36.01%
- Short % of float
- 3.74%
- 50-day average
- 1.27
- 200-day average
- 1.74
Analyst view
Consensus: buy
- Target (low)
- 10.00
- Target (mean)
- 13.67
- Target (high)
- 20.00
- Strong buy0
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 11, 2024
Expected Nov 11, 2024. Consensus EPS estimate -0.25.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2024 | Sep 1, 2024 | -0.30 | — | — | — |
| Aug 13, 2024 | Jun 1, 2024 | -0.29 | — | — | — |
| May 10, 2024 | Mar 1, 2024 | -0.18 | — | — | — |
| Mar 8, 2024 | Dec 1, 2023 | -0.07 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | -0.32 | — | — | — |
| Aug 11, 2023 | Jun 1, 2023 | -0.36 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 23, 2024 | Canaccord Genuity | main | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 14, 2024 | Canaccord Genuity | main | Buy | Buy |
| May 13, 2024 | Canaccord Genuity | main | Buy | Buy |
| May 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 20, 2024 | Alliance Global Partners | main | Buy | Buy |
About Ocuphire Pharma, Inc.
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- opusgtx.com
News
The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics 
Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal 
Shareholder Alert: Ademi LLP Investigates Whether Ocuphire Pharma, Inc. Is Breaching Its Duties to Its Public Shareholders 
Ocuphire Pharma Announces Acquisition of Opus Genetics 
Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology 
UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia 
Ocuphire Pharma, Inc. (OCUP) Reports Q2 Loss, Lags Revenue Estimates 
Ocuphire Pharma to Present at Two Investor Conferences in August 
Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July 
Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June
Your note
Sign in to keep a note on OCUP — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 3.79% | 992,200 | 1.16M | Jun 29, 2024 |
| Geode Capital Management, LLC | 1.01% | 265,854 | 311.05K | Jun 29, 2024 |
| Rice, Hall, James & Associates | 0.85% | 223,589 | 261.60K | Jun 29, 2024 |
| Richmond Brothers, Inc. | 0.73% | 191,304 | 223.82K | Jun 29, 2024 |
| Bridgeway Capital Management, Inc. | 0.63% | 163,741 | 191.58K | Jun 29, 2024 |
| Blackrock Inc. | 0.41% | 106,935 | 125.11K | Jun 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.58% | 675,815 | 790.70K | Jun 29, 2024 |
| Vanguard Extended Market Index Fund | 1.10% | 288,947 | 338.07K | Jun 29, 2024 |
| Fidelity Extended Market Index Fund | 0.61% | 159,100 | 186.15K | Aug 30, 2024 |
| Bridgeway Fds Inc-Omni Small Cap Value Fund | 0.31% | 80,400 | 94.07K | Jun 29, 2024 |
| Clearwater Select Equity Fund | 0.25% | 65,441 | 76.56K | Jun 29, 2024 |
| iShares Micro Cap ETF | 0.22% | 58,047 | 67.91K | Sep 29, 2024 |